Clinical Trial Update: Phase I Trial of PX-478 [Phase 1]

View source ↗

Summary

This Phase I trial of PX-478 has completed. The study involved patients with lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma

Drugs mentioned

• PX-478

Snippet

Sponsor: Cascadian Therapeutics Inc. | Conditions: Advanced Solid Tumors, Lymphoma | Phase 1 | Status: COMPLETED